Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference

Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that it will be presenting at the Q4 Investor Summit Micro & Small Cap Conference (“Q4 Investor Summit”). The event is being held virtually from November 16-17, 2021.

Conference Date: November 16-17, 2021 (Tuesday-Wednesday)
Presentation Time 11:45am - 12:15pm ET - Wednesday, November 17, 2021
Presentation Link: https://us06web.zoom.us/webinar/register/WN_yM_vIgQbSNymul4_b8NvTQ
1:1 Availability: 8am - 4:45pm ET daily
Event Registration https://investorsummitgroup.com

During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will highlight the Company's addition of its Chief Scientific Officer, progress being made with its drug discovery programs, noteworthy collaborations and partnerships, and the broader going-forward corporate strategy.  

The presentation will be webcast and an archived recording will be made available in the Investors’ section of the Vyant Bio website and also on the Q4 Investor Summit website for 90 days following the event.

If you are an investor and would like to attend the Q4 Investor Summit, please click on the following link (https://investorsummitgroup.com) to register. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.

Vyant Bio will also be available for virtual outside 1:1 meetings both during and after the Q4 Investor Summit Micro & Small Cap Conference. Please contact Jennifer K. Zimmons, PhD at jzimmons@zimmonsic.com or +1 917.214.3514 for scheduling.

ABOUT VYANT BIO, INC.

Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering neurology and oncology drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia. The Company has five state-of-the-art labs and a scientific team with world experts in key areas who have been involved in over 200 investigational new drug applications and over 50 CNS and oncology studies and trials.

For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedInhttps://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

Investor Contact:
Jennifer K. Zimmons, PhD, MBA
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514

###


Primary Logo

Source: Vyant Bio, Inc.